Thanks just bought another 2k pre market she is going to run hard you can make book on that.
most undervalued gene editing platform AI computational application for green industrial & green agriculture including cannabis, fruits vegetables insects. And Biotech
Biotech subsidiary Biomica
Proof of concept, first-in-man study – Immuno-oncology program.
https://www.biomicamed.com/
EVGN Biomica microbiome-based therapeutics for immunology looks superior to Seres Therapeutics technology 2.5 billion company that went from 2.52-38.00
Seres therapeutics 2.4 billion market cap.
EVGN Biomica 200 million market cap.
EVGN has the superior tech look for a monster move into double digit dollars coming soon.
https://www.evogene.com/
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.
$EVGN
most undervalued gene editing platform AI computational application for green industrial & green agriculture including cannabis, fruits vegetables insects. And Biotech
Biotech subsidiary Biomica
Proof of concept, first-in-man study – Immuno-oncology program.
https://www.biomicamed.com/
EVGN Biomica microbiome-based therapeutics for immunology looks superior to Seres Therapeutics technology 2.5 billion company that went from 2.52-38.00
Seres therapeutics 2.4 billion market cap.
EVGN Biomica 200 million market cap.
EVGN has the superior tech look for a monster move into double digit dollars coming soon.
https://www.evogene.com/
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.
$EVGN
Recent EVGN News
- Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN) • IH Market News • 05/20/2026 01:59:09 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 12:45:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2026 11:00:14 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 08:01:21 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 03:17:06 PM
- Evogene to Present at the 24th Schrödinger European User Group Meeting • PR Newswire (US) • 05/12/2026 12:00:00 PM
- Evogene Schedules First Quarter 2026 Financial Results Release • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 08:01:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 08:03:36 PM
- Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 04/02/2026 08:01:00 PM
- Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock • PR Newswire (US) • 03/31/2026 12:00:00 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 03/26/2026 08:30:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/26/2026 08:28:33 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/26/2026 08:26:46 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/26/2026 08:00:39 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:27:44 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:06:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:03:42 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:00:07 PM
- Evogene Reports Fourth Quarter and Full Year 2025 Financial Results • PR Newswire (US) • 03/05/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 01:00:32 PM
- Evogene Releases CEO Letter to Shareholders • PR Newswire (US) • 02/25/2026 01:00:00 PM
